A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. This phase 2, open-label study evaluated the safety and antitu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Sharman, Jeffrey P., Wheler, Jennifer J., Einhorn, Lawrence, Dowlati, Afshin, Shapiro, Geoffrey I., Hilton, John, Burke, John M., Siddiqi, Tanya, Whiting, Nancy, Jalal, Shadia I.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Phase II Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647393/
https://ncbi.nlm.nih.gov/pubmed/30993587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00768-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados